Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 04:03:25 2024-05-06 pm EDT			5-day change	1st Jan Change
127.6 ^USD	+0.04%		-1.96%	+17.02%

May. 02	Merck: encouraging results in gastric cancer	CF
May. 01	Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merck: encouraging results in gastric cancer	May. 02	CF
Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial	May. 01	MT
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	May. 01	CI
BioMed X Announces the Start of A New Research Project in Partnership with Merck	Apr. 30	CI
Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine	Apr. 29	MT
Blackstone beats Concord with $1.6 bln bid for Hipgnosis Songs	Apr. 29	RE
Habeck's 'pharma trip' - industry sees structural problems	Apr. 29	DP
AbbVie raises annual profit forecast on strong Skyrizi sales	Apr. 26	RE
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
The specter of stagflation rears its ugly head again	Apr. 25
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat	Apr. 25	MT
Merck raises annual target ranges	Apr. 25	CF
Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised	Apr. 25	MT
(MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.78B	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Posts Q1 EPS $2.07	Apr. 25	MT
Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024	Apr. 25	CI
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales	Apr. 25	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Highlights

Filters